Pharmacological treatment of impulsivity and aggressive behavior;Tratamento farmacológico da impulsividade e do comportamento agressivo

Revista Brasileira de Psiquiatria

Volumn 31, Issue SUPPL. 2, 2009, Pages

  Do Prado Lima, Pedro Antônio Schmidt ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Aggression; Borderline personality disorder; Impulsive behavior; Neurological manifestations; Symptoms, mental

Indexed keywords

BUSPIRONE; CARBAMAZEPINE; CLONIDINE; CLOZAPINE; DOCOSAHEXAENOIC ACID; DOPAMINE; ICOSAPENTAENOIC ACID; LITHIUM; METHYLPHENIDATE; NADOLOL; NORADRENALIN; OLANZAPINE; OXCARBAZEPINE; PINDOLOL; PROPRANOLOL; QUETIAPINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID;

AGGRESSION; AMYGDALOID NUCLEUS; ANGER; ASTHMA; BEHAVIOR DISORDER; CONDUCT DISORDER; DIZZINESS; HOSTILITY; HUMAN; IMPULSIVENESS; LIMBIC CORTEX; MENTAL DISEASE; NEUROBIOLOGY; NEUROLOGIC DISEASE; OPPOSITIONAL DEFIANT DISORDER; PREFRONTAL CORTEX; PSYCHOPHARMACOTHERAPY; REVIEW; SUICIDE;

EID: 73549095212     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462009000600004     Document Type: Review

References (66)

1. Blair RJ. The roles of orbital frontal cortex in the modulation of antisocial behavior. Brain Cogn. 2004;55(1):198-208.
2. Blair RJ. Dysfunctions of medial and lateral orbitofrontal cortex in psychopathy. Ann N Y Acad Sci. 2007;1121: 461-79.
3. Siever LJ. Neurobiology of aggression and violence. Am J Psychiatry. 2008;165(4):429-42,
4. Raine A, Yang Y. Neural foundations to moral reasoning and antisocial behavior. Soc Cogn Affect Neurosci. 2006;1(3):203-13.
5. New AS, Hazlett EA, Buchsbaum MS, Goodman M, Mitelman SA, Newmark R, Trisdorfer R, Haznedar MM, Koenigsberg HW, Flory J, Siever LJ. Amygdala-prefrontal disconnection in borderline personality disorder. Neuropsychopharmacology. 2007;32(7):1629-40.
6. Damasio H, Grabowsky T, Frank R, Galaburda AM, Damasio AR. The return of Phineas Cage: clues about the grain from the skull of a famous patient. Science. 1994;264(5162):1102-5.
7. Pietrini P, Guazzelli M, Basso G, Jaffe K, Grafman J. Neural correlates of imaginal aggressive behavior assessed by positron emission tomography in healthy subjects. Am J Psychiatry. 2000;157(11):1772-81.
8. Minzenberg MJ, Fan J, New AS, Tang CY Siever LJ. Frontlimbic dysfunction in response to facial emotion in borderline personality disorder: an event-related fMRI study. Psychiatry Res. 2007;155(3):231-43.
9. Siegel A, Bhatt S, Bhatt R, Zalcman SS. The neurobiological bases for development of pharmacological treatments for aggressive disorders. Curr Neuropharmacol. 2007;5(2):135-47.
10. Åsberg M, Träskman L, Thoren P. 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Arch Gen Psychiatry. 1976;33(10):1193-7.
11. Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, Mohs RC, Davis KL. Serotonergic studies in affective and personality disorder: correlates with suicidal and impulsive aggressive behavior. Arc Gen Psychiatry. 1989;46(7):597-99.
12. Coccaro EF, Lawrence T, Trestman R, Gabriel S, Klar HM, Siever LJ. Growth hormone response to intravenous clonidine challenge correlate with behavioral irritability in psychiatric patients and health volunteers. Psychiatry Res. 1991;39(2):129-39.
13. Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS. Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Can Acad Child Adolesc Psychiatry. 2006;15(1):27-39.
14. Cammarota M, Bevilaqua LR, Rossato JI, Lima RH, Medina JH, Izquierdo I. Parallel memory processing by the CA1 region of the dorsal hippocampus and the basolateral amygdala. Proc Natl Acad Sci USA. 2008;105(30):10279-84.
15. Barros DM, Izquierdo LA, Mello e Souza T, Ardenghi PG, Pereira P, Medina JH, Izquierdo I. Molecular signalling pathways in the cerbral cortex are reuired for retrival of one-trial avoidance learning in rats. Behav Brain Res. 2000;114(1-2):183-92.
16. Ferris CF, Stolberg T, Kulkarni P, Murugavel M, Blanchard R, Blanchard DC, Febo M, Brevard M, Simon NG. BMC Neurosci. 2008;9:111.
17. Goedhard LE, Stolker JJ, Heerdink ER, Nijman HL, Oliver B, Egberts TC. J Clin Psychiatry. 2006;67(7):1013-34.
18. Bierbrauer J, Nilsson A, Müller-Oerlinghausen B, Bauer M. Therapeutic and prophylatic effects of lithium on pathological aggression. In: Bauer M,Grog P, Müller-Oerlinghausen B. Lithium in neuropsychiatry. Abingdon: Informa; 2006.p.227-36.
19. Sheard MH. Effect of lithium in human aggression. Nature. 1971;230:113-4,
20. Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry. 1976;133(12):1409-13.
21. do Prado-Lima PA, Knijnick L, Juruena M, Padilla A. Lithium reduces maternal child abuse behavior: a preliminary report. J Clin Pharm Ther. 2001;26(4):279-82.
22. Goodwin FK, Fireman B, Simon GE, Hunkelel EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290(11):1467-73.
23. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolan, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45(2):111-9.
24. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155(1):54-61.
25. Stanford MS, Helfritz LE, Conklin SM, Villemarette-Pittman NR, Grve KW, Adams D, Houston RJ. A comparison of anticonvulsants in the treatment of impulsive aggression. Exp Clin Psychopharmacol. 2005;13(1):72-7.
26. Mattes JA. Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo controlled trial. J Clin Psychopharmacol. 2005;25(6):575-9.
27. Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv. 2004;55(3):290-4.
28. Gobbi G, Gaudreau PO, Leblanc N. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J Clin Psychophamacol. 2006;26(5):467-73.
29. Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW, Nemeroff CB. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28(6):1186-97.
30. Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005;162(3):621-4.
31. Simeon D, Baker B, Chaplin W, Braun A, Hollaqnder E. An open label-trail of divalproex extended-release in the treatment of borderline personality disorder. CNS Spectr. 2007;12(6):439-43.
32. Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, Rother WK, Loew TH. Topiramate treatment of aggression in female borderline personality disorder: a double blind, placebo-controlled study. J Clin Psychiatry. 2004;65(11):1515-9.
33. Nickel MK, Nickel C, Kaplan P, Lahmann C, Mühlbacher M, Tritt K, Krawczyk J, Leiberich PK, Rother WK, Loew TH. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005;57(5):495-9.
34. Nickel MK, Loew TH. Treatment of aggression with topiramate in male borderline patients, part II: 18-months follow-up. Eur Psychiatry. 2008;23(2):115-7.
35. Schmidt do Prado-Lima PA, Bacaltchuck J. Topiramate in treatmentresistant depression and binge-eating disorder. Bipolar Disord. 2002;4(4):271-3.
36. do Prado-Lima PA, Kristensen CH, Bacaltchuck J. Can childhood trauma predict response to topiramate in borderline personality disorder? J Clin Pharm Ther. 2006;31(2):193-6.
37. Buydens-Branchey L, Branchey M, Hibbeln JR. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):568-75.
38. Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind placebo-controlled pilot study. Am J Psychiatry. 2003;160(1):167-9.
39. Seung Kim HF, Weeber EJ, Sweatt JD, Stoll AL, Marangell LB. Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Mol Psychiatry. 2001;6(2):246-8.
40. Hibbeln JR. Long-chain polyunsaturated fatty acids in depression and related conditions. In: Peet M, Glen I, Horrobin DF. Phospholipid spectrum disorder in psychiatry. Carnforth: Marius Press; 1999. p.195-210.
41. Greendyke RM, Kanter DR, Schuster DB, Verstreate S, Wootton J. Propanolol treatment of assaultive patients with organic brain disease. A double-blind crossover, placebo controlled study. J Nerv Ment Dis. 1986;174(5):290-4.
42. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry. 1986;47(8):423-6.
43. Silver JM, Yudofsky SC, Slater JA, Gold RK, Stryer BLK, Williams DT, Wolland H, Endicott J. Propranolol treatment of chronically hospitalized aggressive patients. J Neuropsychiatry Clin Neurosci. 1999;11(3):328-35.
44. Rattey JJ, Sorgi P, O'Driscoll GA, Sands S, Daehler ML, Fletcher JR, Kadish W, Spruiell G, Pollakoff S, Lindem KJ, Bemporad JR, Richardson L, Rosenfeld B. Nadolol to treat aggression and psychiatry symptomatology in chronic psychiatric inpatients: a double-blind placebo controlled study. J Clin Psychiatry. 1992;53(2):41-6.
45. Yudofsky SC, Silver JM, Hales RE. Treatment of aggressive disorders. In: Schatzberg AF, Nemeroff CB. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press; 1995. p,735-51.
46. Knutson B, Wolkowitz OM, Cole SW, Chan T, Moore EA, Johnson RC, Terpstra J, Turner RA, Reus VI. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry. 1998;155(3):373-9.
47. Silva H, Iturra P, Solari A, Villarroel J, Jerez S, Vielma W, Montes C, Pumarino L, Roa N. Serotonin transporter polymorphism and fluoxetine effect on impulsiveness and aggression in borderline personality disorder. Actas Esp Psiquiatr. 2007;35(6):387-92.
48. Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, Cooper TB, Chacos M, Lieberman JA. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv. 2001;52(11):1510-4.
49. Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Lieberman JA. Overt aggression on psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopahrmacol. 2004;24(2):225-8.
50. Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006;63(6):622-9.
51. Kraus JE, Sheitman BB. Clozapine reduces violent behavior in heterogeneous diagnostic group. J Neuropsychiatry Clin Neurosci. 2005;17(1):36-44.
52. Chengappa KN, Ebeling P, Kang JS, Levine J, Parepally H. Clozapine reduces severer self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry. 1999;60(7):477-84.
53. Swanson JW, Swartz MS, Elbogen EB, Van Dorn RA. Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. J Clin Psychiatry. 2004;65(12):1666-73.
54. Schulz SC, Camlin KL, Berry SA, Jesberger JA, Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999;46(10):1429-35.
55. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebocontrolled pilot study. J Clin Psychiatry. 2001;62(11):849-54.
56. Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E, Pérez V. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162(6):1221-4.
57. Janowsky DS, Barnhill LJ, Davis JM. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open label, naturalistic trial. J Clin Psychiatry. 2003;64(10):1258-65.
58. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer diseases in nurse care facilities: a double-blind, randomized, placebo-controlled trail. The HGEU Study Group. Arch Gen Psychiatry. 2000;57(10):968-76.
59. Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol. 2008;18(2):140-56.
60. Van den Eynde F, Senturk V, Naudts K, Vogels C, Bernagie K, Thas O, van Heeringem C, Audenaert K. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol. 2008;28(2):147-55.
61. Sinzig J, Döpfner M, Lehmkuhl G, German Methylphenidate Group, Uebel H, Schmeck K, Poustka F, Gerber WD, Günter M, Knölker U, Gehrke M, Hässler F, Resch F, Brünger M, Ose C, Fischer R. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17(4):421-32.
62. Verhoeven WM, Tuinier S. The effect of buspirone on challenging behavior in mentally retarded patient: an open prospective multiplecase study. J Intellect Disabil Res. 1996;40(Pt 6):502-8.
63. Charney DS, Sternberg DE, Kleber HD, Heninger GR, Redmond DE Jr. The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch Gen Psychiatry. 1981;38(11):1273-7.
64. Hardy MC, Lecrubier Y, Widlöcher D. Efficacy of clonidine in 24 patients with acute mania. Am J Psychiatry. 1986;143(11):1450-3.
65. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila). 2000;39(1):15-25.
66. Kemph JP, DeVane CL, Levin GM, Jarecke L, Miller RL. Treatment of aggressive children with clonidine: results of an open pilot study. J Am Acad Child Adolesc Psychiatry. 1993;32(3):577-81.